36 results about "Liver enzyme" patented technology

The invention relates to a self-management behavior auxiliary system for gestation and epilepsy patients, and belongs to the technical field of medical monitoring and diagnosis. The auxiliary system comprises a detection unit used for obtaining physiological parameters, related to pregnancy combined epilepsy, of a patient; the processing unit is used for analyzing and processing the data obtained by the detection unit so as to evaluate the health trend of the patient, and the physiological parameters obtained by the detection unit comprise the blood concentration, the liver enzyme activity and the blood sugar level. The processing unit can calculate and obtain a gestational epilepsy management index used for representing the health trend of the patient based on the physiological parameters so as to judge the epilepsy risk condition of the patient in the current gestational period.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

How to treat injuries or conditions associated with CNS edema [Solution] This technology relates to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the method includes reducing late neurological exacerbations or preventing death, reducing midline deviation of the brain, reducing the degree of functional impairment in subjects, neutralizing blood glucose levels in subjects receiving SUR1-TRPM4 channel inhibitors, preventing cerebral swelling, treating injuries or conditions associated with CNS edema while monitoring liver enzyme activity, or treating injuries or conditions associated with CNS edema while monitoring cardiac activity.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The invention provides a composition. The composition is prepared from spleen aminopeptide, phycocyanin, folic acid substances and health-care food or medicine acceptable auxiliary materials. The composition disclosed by the invention has the advantages that the composition has a synergistic effect, can effectively reduce liver enzyme, improve degeneration and necrosis of liver cells and relieve chemical liver injury, has an immune regulation effect and can inhibit liver inflammatory response, so that the composition can be used for assisting in preventing and treating the chemical liver injury. In addition, the multi-component compound form of the product can obviously improve the taking compliance of users, and the total use cost is saved.

The invention provides an anti-alcohol functional water based on liver enzyme activation, and relates to the technical field of functional water. The hangover alleviating functional water based on liver enzyme activation is prepared from radix puerariae isoflavone aglycone, globe artichoke water-soluble polysaccharide, emblic leafflower fruit procyanidine oligomer, an electrolyte combination, a pH buffer system, hovenia dulcis thunb, fructus gardeniae, beta-nicotinamide mononucleotide, hydrogen-rich water, vitamin C, vitamin E and curcumin, and the electrolyte combination is prepared from sodium chloride, potassium chloride and sodium bicarbonate. Alcohol dehydrogenase and acetaldehyde dehydrogenase in the liver can be activated through the radix puerariae isoflavone aglycone, the globe artichoke water-soluble polysaccharide, the emblic leafflower fruit proanthocyanidin oligomer and the like, so that decomposition and metabolism of alcohol are accelerated, the retention time of the alcohol in the body can be remarkably shortened by activating the enzymes and dispelling drunkenness, and the symptoms of drunkenness and hangover are reduced.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

This invention relates to the field of livestock and poultry breeding and food safety testing technology, and in particular to a method for assessing copper exposure hepatotoxicity based on the endoplasmic reticulum stress-endoplasmic reticulum autophagy axis and its application. This method obtains liver tissue samples or in vitro cultured hepatocyte samples from copper-exposed subjects, and jointly detects the expression levels of key markers of the endoplasmic reticulum stress pathway and characteristic markers of the endoplasmic reticulum autophagy pathway. Combined with two-way pharmacological validation, a grading assessment standard for copper exposure hepatotoxicity is established. This invention overcomes the shortcomings of traditional liver enzyme indicators, such as low sensitivity and strong lag, and has the advantages of early warning, high specificity, and reliable results. It can be widely applied to scenarios such as determining the copper safety threshold in livestock and poultry feed, early screening for copper exposure hepatotoxicity, assessment of copper pollution ecological risks, and screening of copper toxicity protectants, providing technical support for ensuring animal health and the safety of animal-derived food.

The application discloses an anti-hepatic fibrosis small-molecule compound and application, which is composed of 3beta-ethoxy artenimol and 6-hydroxy kaempferol, and is used as an anti-hepatic fibrosis drug after splenectomy. The application can improve the hepatic fibrosis degree after splenectomy (reduce liver inflammation, improve liver enzyme spectrum, reduce bilirubin, and reduce collagen deposition), and the causes of liver fibrosis include at least one of alcoholic hepatitis, fatty liver, viral hepatitis, drug-induced hepatitis, autoimmune hepatitis and the like.

The present application relates to a death risk prediction model for severe burn combined with liver enzyme abnormality, a construction method and a storage medium. The construction method of the death risk prediction model comprises: collecting clinical feature data of patients with severe burn combined with liver enzyme abnormality; using an RF-RFE joint regression model to analyze and screen the clinical feature data of the training set and whether to die, and screening out the clinical feature data related to death of severe burn combined with liver enzyme abnormality; and based on the screened clinical feature data, a death risk prediction model is constructed. The present application also provides a death risk prediction model constructed by the construction method. The present application also provides a storage medium. Based on the clinical basic data and disease-related indicators of patients, the present application identifies the risk factors leading to the death of patients with severe burn and liver enzyme abnormality, so as to predict the death probability of patients in advance, conveniently, quickly and accurately, thereby helping doctors to take corresponding prevention and treatment measures for patients.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

This article describes methods, compositions, and systems derived from uncultured microorganisms that can be used to supplement liver enzyme deficiencies.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The application belongs to the technical field of microorganisms and their application, and specifically discloses a mucinophilic Akkermansia strain, a high-activity reserved inactivation method of the strain and application of the strain. The strain has a preservation number of CGMCC No. 33955, and when the strain is cultured in a mucin only carbon source culture medium for 48 hours, the OD600 value reaches 1.32 and the acetic acid yield is 18.3 mmol / L. The inactivation method uses a solution containing sulfated dextran, sucrose and epsilon-polylysine as a composite protective agent, and after the solution is mixed with the bacterial solution, the mixture is incubated at 45 DEG C to 50 DEG C for 16 min to 20 min. The inactivated strain reduces inflammation and protects lung vascular function through the "gut-lung axis", and in a MCT-induced PAH rat model, the intervention effect is close to sildenafil, and there is no increase in liver enzymes, the serum TNF-alpha and IL-6 are reduced, and the problems of large side effects and low activity reservation of existing PAH intervention are solved.

The invention discloses a medicinal and edible traditional Chinese medicine compound for treating simple obesity rather than alcoholic fatty liver and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of lotus leaves, 15 to 25 parts of semen cassiae, 8 to 18 parts of spica prunellae, 15 to 25 parts of fructus crataegi, 10 to 20 parts of flos lonicerae, 10 to 20 parts of semen persicae, 7 to 17 parts of rhizoma curcumae longae, 10 to 20 parts of radix angelicae sinensis, 2.5 to 12.5 parts of fructus mume and 1 to 6 parts of radix glycyrrhizae. The traditional Chinese medicine compound is composed of medicinal and edible raw materials and has the efficacy of losing weight and treating non-alcoholic fatty liver, and tests prove that the weight and body fat rate of diet-induced obese mice can be remarkably reduced by taking one dose of the traditional Chinese medicine compound per day, the blood sugar regulation capacity of organisms is improved, liver fatty degeneration is improved, and the non-alcoholic fatty liver disease is reduced. And the levels of serum liver enzyme and biochemical factors are reduced, so that the compound disclosed by the invention has good effects of losing weight and relieving fatty liver, and can be used for treating simple obesity and non-alcoholic fatty liver.

A method for identifying a cause of elevated liver enzymes includes receiving new patient data, receiving a machine-learning based diagnostic model and a knowledge based diagnostic model, determining whether the machine-learning based diagnostic model indicates a cause of elevated liver enzymes for the new patient data, and in a case where the machine-learning based diagnostic model indicates the cause of elevated liver enzymes for the new patient data, assessing the cause of elevated liver enzymes using the knowledge based diagnostic model.

The present application discloses a disposable test cartridge and a corresponding cartridge kit and method wherein the test cartridge comprises: a cartridge body having a plurality of chambers, each of the plurality of chambers having an opening at a top of the cartridge body, and at least one of the plurality of chambers comprising a reactant mixture, the reactant mixture comprises a chemical that is specific for catalysis of one of a liver enzyme ALT, AST, ALP, or GGT in a blood sample; a removable cartridge cover connected to the cartridge body and covering the plurality of chambers, the removable cartridge cover having a capillary tube receiving hole and a capillary tube element removably inserted into the cartridge cover, the capillary tube element configured to obtain a blood sample; and a test strip module integrally molded with the cartridge and comprising at least one analyte test strip configured to receive a portion of the reaction solution and measure at least one analyte, the at least one analyte being at least one reaction product.

The application belongs to the technical field of drug research and development, and particularly relates to a cyclophosphamide or ethylene imine prodrug compound, and further discloses the use thereof for preparing a liver-targeting alkylating agent. The compound disclosed in the application is based on traditional nitrogen mustard and derivatives thereof and ethylene imine alkylating agents, and is metabolically activated by a prodrug form through liver enzymes, further enhances the selectivity of the related compounds, reduces the influence on normal cells, and is metabolically activated by cytochrome P450 (CYP450) to release active ingredients, and has a good application prospect in treating liver-related cancers.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

The invention discloses an application of H1152 in preparation of a medicine for treating metabolism-related cognitive impairment, belongs to the technical field of medicine, breaks through the limitation that an existing medicine singly regulates metabolism or cognition, and the H1152 can synchronously inhibit abnormal weight growth induced by high fat diet and remarkably improve spatial memory water maze experiments and short-term memory new object recognition experiments. Dual intervention of metabolism and nerves is realized; compared with statins, the H1152 does not observe creatine kinase rise or liver enzyme abnormity under the equivalent lipid-lowering dosage, and animal experiments show that the H1152 has better safety; the ROCK signal channel is regulated and controlled, and the ROCK signal channel acts on vascular endothelial function improvement and neuronal synaptic plasticity enhancement at the same time, so that the problem of co-disease of metabolism and cognition is solved from the multi-target level; the body weight growth rate, the water maze escape latency and the new object recognition index are integrated as the combined curative effect markers for the first time, and quantifiable objective standards are provided for clinical curative effect evaluation.

The invention discloses a drug-resistant main protease inhibitor with stable metabolism and application thereof in preparation of antiviral drugs. In the main protease inhibitor, a group C not only can be effectively combined with an active pocket of main protease, but also the combination mainly depends on the 163rd amino acid site of the main protease; meanwhile, the group C is relatively difficult to oxidize, so that the main protease inhibitor can show basically consistent inhibitory activity to both mutant strains and wild strains, viruses do not generate drug resistance to the main protease inhibitor, and the main protease inhibitor can tolerate liver drug enzyme metabolism, has excellent drug-resistant activity and metabolic stability, and can be used for preparing the main protease inhibitor. In use, a liver drug enzyme inhibitor does not need to be used cooperatively, and reduction of self liver function decline and toxic and side effects caused by medicine taking is facilitated. In addition, the group A not only can further improve the inhibitory activity of the main protease inhibitor on the main protease, but also can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the ring B mainly plays a role in further improving the inhibitory activity of the main protease inhibitor on the main protease.

The present invention relates to a transient intentional ischemia of a part of the liver by occlusion of a selected hepatic vein, subsequently causing reperfusion injury, useful for the treatment of cancer via the endogenous release of liver enzymes, including liver arginase.

The application discloses a metabolically stable anti-drug-resistant main protease inhibitor and application thereof in preparation of antiviral drugs. In the main protease inhibitor, the group C can be effectively combined with the active pocket of the main protease, and the combination mainly depends on the 163th amino acid site of the main protease; meanwhile, the group C is difficult to be oxidized, so that the main protease inhibitor can exhibit basically consistent inhibitory activity to both mutant strains and wild strains, the virus cannot produce drug resistance to the main protease inhibitor of the application, and the main protease inhibitor has excellent anti-drug resistance activity and metabolic stability, and does not need to be used in combination with a liver enzyme inhibitor when used, which is favorable for reducing self-liver function reduction and toxic side effects caused by drug taking. In addition, the group A can further improve the inhibitory activity of the main protease inhibitor to the main protease, and can enhance the anti-drug resistance activity and metabolic stability of the main protease inhibitor; and the B ring mainly plays a role in further improving the inhibitory activity of the main protease inhibitor to the main protease.

The invention belongs to the technical field of microorganisms and application thereof, and particularly discloses Ackermania muciniphila as well as a high-activity retention and inactivation method and application thereof. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.33955, and when the strain is cultured in a mucoprotein unique carbon source culture medium for 48 hours, the OD600 value reaches 1.32, and the yield of acetic acid is 18.3 mmol / L. According to the inactivation method, a solution containing sulfated dextran, cane sugar and epsilon-polylysine is used as a composite protective agent and is mixed with a bacterial solution, and then the temperature of 45-50 DEG C is kept for 16-20 min. The inactivated strain reduces inflammation and protects the pulmonary vascular function through an intestine-lung axis, in an MCT-induced PAH rat model, the curative effect after intervention is close to that of sildenafil, liver enzyme rise and serum TNF-alpha and IL-6 reduction do not exist, and the problems that existing PAH intervention is large in side effect and low in activity retention are solved.

The invention discloses a broccoli extract, a preparation method thereof and application of the broccoli extract in preparation of products for adjuvant therapy of fatty liver diseases related to metabolic dysfunction, belongs to the technical field of plant extracts, and particularly relates to a preparation method of the broccoli extract, which comprises the following steps: cleaning, cutting and drying broccoli leaves to obtain dried broccoli leaves, crushing, sieving, and drying to obtain the broccoli extract. And dispersing the broccoli leaf powder in distilled water, carrying out ultrasonic extraction to obtain a broccoli leaf extracting solution, centrifuging, collecting supernate, and carrying out vacuum freeze drying to obtain the broccoli extract. The broccoli extract is applied to preparation of products for prevention and / or adjuvant therapy of fatty liver diseases related to metabolic dysfunction. The broccoli leaf extract prepared by the preparation method provided by the invention is proved to be capable of remarkably inhibiting weight gain, improving glucose tolerance and insulin sensitivity and reducing serum lipid level and liver enzyme activity by utilizing a mouse high fat diet induced MAFLD prevention and treatment model.

The invention discloses an application of COLEC11 protein in prevention and treatment of a non-alcoholic fatty liver disease. The invention discovers that the expression quantity of the COLEC11 protein is related to the non-alcoholic fatty liver disease or the non-alcoholic steatohepatitis; specifically, the expression of COLEC11 in the liver of NAFLD and NASH mice is significantly up-regulated, and more importantly, the level of circulating COLEC11 of a patient with NAFLD is significantly increased and is positively correlated with the levels of serum liver enzymes ALT and AST of the patient. The COLEC11 in the mouse liver is overexpressed by using the adenovirus, so that fat accumulation of the mouse liver is increased, and inflammation and fibrosis formation are promoted. The discovery shows that abnormal increase of liver COLEC11 expression can promote occurrence and development of the non-alcoholic fatty liver disease or the non-alcoholic steatohepatitis. The invention provides a new potential diagnosis and treatment target for the non-alcoholic fatty liver disease or the non-alcoholic steatohepatitis.

The application relates to the field of nano drug loading technology, and discloses application of beta-glucan in preparation of liver-targeted drugs for treating liver cancer and the liver-targeted drugs, wherein the beta-glucan is derived from black fungus, and a chemical structural formula of the beta-glucan is that two beta-(1, 6)-glucose residues are arranged on the side chain of every three beta-(1, 3)-glucose main chains. The application provides a new use of black fungus beta-glucan in preparation of liver-targeted drugs for treating liver cancer. The black fungus beta-glucan has the abilities of liver targeting, enzymatic release and activation of macrophages, so that the black fungus beta-glucan can be used as a carrier of the liver-targeted drugs, the drugs can be stably delivered to the liver, and the release of the drugs is realized under the action of liver enzymes in the liver, so that the liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma, etc.) can be effectively treated, the toxic side effect is small, and the drug carrier can have a synergistic effect with the drugs loaded thereon, so that the intrahepatic cholangiocarcinoma can be better treated.